{
    "clinical_study": {
        "@rank": "23497", 
        "acronym": "MYELOME-PA", 
        "arm_group": {
            "arm_group_label": "NA/NA", 
            "arm_group_type": "No Intervention"
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is to determine whether the presence of vulnerability detected by\n      geriatricians is associated with treatment discontinuation in older patient. During the\n      comprehensive geriatric assessment realized before the decision-treatment, the following\n      data are recorded and their impact in the therapeutic changes will also be analysed:\n      comorbidity, age, depression, functional status, the cognitive impairment and malnutrition."
        }, 
        "brief_title": "Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma in Older Patients", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged 70 years and older\n\n          -  Patients referred for a assessment of a newly diagnosed multiple myeloma\n\n          -  Patients for who the initial therapy proposed is either\n             melphalan-prednisone-thalidomide or melphalan-prednisone-bortezomib or included in a\n             phase 3 trial.\n\n          -  Patients who provide informed written consent\n\n        Exclusion Criteria:\n\n          -  Patients who refuse the study\n\n          -  Patients who won't have therapy\n\n          -  Patients can't respond to geriatric assessment  because of severe cognitive disorder\n\n          -  Patients with a legal guardian"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "70 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063113", 
            "org_study_id": "RC13_0437"
        }, 
        "intervention": {
            "arm_group_label": "NA/NA", 
            "intervention_name": "Vulnerability and therapeutic changes in older patients with multiple myeloma.", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple myeloma,", 
            "Older patient,", 
            "Treatment,", 
            "Geriatric assessment"
        ], 
        "lastchanged_date": "February 12, 2014", 
        "location": {
            "contact": {
                "email": "laure.dedecker@chu-nantes.fr", 
                "last_name": "Laure De Decker, Dr"
            }, 
            "facility": {
                "address": {
                    "city": "Nantes", 
                    "country": "France", 
                    "zip": "44000"
                }, 
                "name": "CHU de Nantes"
            }, 
            "investigator": {
                "last_name": "Laure De Decker, Dr", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.", 
        "overall_contact": {
            "email": "laure.dedecker@chu-nantes.fr", 
            "last_name": "Laure De Decker, Dr"
        }, 
        "overall_official": [
            {
                "affiliation": "CHD Vend\u00e9e La Roche sur Yon", 
                "last_name": "Komivi AGBETSIVI, DR", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CH du Mans", 
                "last_name": "VIGNARD Patricia, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Rennes University Hospital", 
                "last_name": "Catherine Cattenoz, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHU de Brest", 
                "last_name": "Jean -Richard EVEILLARD, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHU de Lille", 
                "last_name": "Fran\u00e7ois Puisieux, Pr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHU de Nancy", 
                "last_name": "Jean -Yves NIEMIER, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CGD de Marseille", 
                "last_name": "Fr\u00e9d\u00e9rique Retornaz, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "H\u00f4pital Europ\u00e9en de Marseille", 
                "last_name": "V\u00e9ronique Brunel, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHU de Nantes", 
                "last_name": "Laure De Decker, Dr", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Committee for the Protection of Personnes", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome is either :\nearly interruption of treatment\ndose reduction > 20% during treatment\ndiscontinuous treatment\nThese outcomes will be measured every 6 months during the 2 years of follow up", 
            "measure": "The occurrence of the events", 
            "safety_issue": "Yes", 
            "time_frame": "6 MONTHS"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063113"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "vulnerability related to toxicities, vulnerability related to multiple myeloma or geriatric vulnerability.", 
                "measure": "Type of Vulnerability", 
                "safety_issue": "Yes", 
                "time_frame": "6 MONTHS"
            }, 
            {
                "description": "early interruption of treatment, dose reduction during treatment, discontinuous treatment", 
                "measure": "Therapeutic changes", 
                "safety_issue": "Yes", 
                "time_frame": "6 MONTHS"
            }, 
            {
                "description": "hematologic toxicity, neurotoxicity, gastrointestinal toxicity, deep vein thrombosis, pulmonary embolism, infections with antibiotic use", 
                "measure": "Toxicity during treatment", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Progression to 1 and 2 years", 
                "safety_issue": "Yes", 
                "time_frame": "1 year/2year"
            }, 
            {
                "measure": "Complete response at 1 and 2 years", 
                "safety_issue": "Yes", 
                "time_frame": "1 year/2 years"
            }
        ], 
        "source": "Nantes University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nantes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}